#339 Is Berberine Nature's Ozempic?

#339 Is Berberine Nature's Ozempic?

The Breast Cancer Recovery Coach

In 2023, the dietary supplements market was valued at approximately $167.5 billion to $177.5 billion. So it is no surprise when we see headlines touting the latest and greatest new supplement, that it’s benefits can be overstated and lots of people...

InformativeEmpoweringSupportiveEducationalThought-provoking

21:4423 Apr 2024

RSS Feed

Berberine: Miracle Supplement or Just Hype?

Episode Overview

  • Berberine's similarity to prescription drug Ozempic in weight management
  • Studies showing Berberine's impact on type 2 diabetes, cholesterol, and weight
  • Considerations on safety, interactions, and potential side effects
  • The importance of consulting healthcare providers before supplementing
  • Embracing mindful health approaches for personalized wellness journeys
Natural substances also have powerful effects, right? Herbal medicine is medicine. And we can't forget that.

In this episode of 'Better Than Before Breast Cancer', Laura Lummer dives into the buzz around Berberine, a supplement making waves on social media. Touted as 'Nature's Ozempic', Berberine has caught the attention of many for its potential health benefits. Laura, who personally uses the supplement, takes you through what Berberine is, where it comes from, and what scientific studies say about its effects on type 2 diabetes, weight management, and cholesterol levels.

She also touches on its potential anti-cancer properties. But before you rush to add it to your daily routine, Laura emphasizes the need to consult with a healthcare provider due to possible interactions and side effects. If you're curious about whether Berberine is worth the hype, this episode offers a balanced view backed by science and personal experience.

Podcast buttons

Do you want to link to this podcast?
Get the buttons here!

More From This Show

The latest episodes from the same podcast.

Related Episodes

Similar episodes from other shows in the catalogue.